P-selectin glycoprotein ligand 1 (PSGL-1) is central to the trafficking of immune effector cells to areas of inflammation through direct interactions with P-selectin, E-selectin and L-selectin.

SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc. ("Verseau") today announced the ...

Incidence and risk factors for pneumonitis associated with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer: A single center experience. This is an ASCO Meeting Abstract from ...

New research has identified a new regulator of immune responses. The study sheds new light on why T cells fail to clear chronic infections and eliminate tumors. Research led by scientists at the ...

The protein, P-selectin glycoprotein ligand 1 (PSGL-1), which exists in human cells, can inhibit the process by which HIV replicates, according to research published in the science journal Nature ...

Addady, Today established, landed in PSGL’s office early this week. Today can confirm that this latest invitation to PSGL’s board of directors is in connection with an ongoing investigation ...

"We are pleased to continue building evidence of ALTB-268’s potential to treat T-cell-mediated inflammatory diseases, through its unique mechanism of action as an immune checkpoint enhancer targeting ...

Their decision to select VTX-0811 as the first program for development validates that PSGL-1 is an important and novel immuno-oncology target with the potential to expand the number of patients ...

Their decision to select VTX-0811 as the first program for development validates that PSGL-1 is an important and novel immuno-oncology target with the potential to expand the number of patients ...